Clinical Trial Update: Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy

View source ↗

Summary

This clinical trial update reports that the study evaluating a pharmacogenetic testing panel to identify patients at risk for pharmacogenetics-related adverse e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Capecitabine (Xeloda) (Capecitabine)
• Irinotecan (Camptosar) (Irinotecan)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Cancer | Status: COMPLETED